Pharmacokinetics of amrubicin in lung cancer patients with impaired hepatic function

Cancer Treatment and Research Communications - Tập 9 - Trang 81-87 - 2016
Shinichiro Ryuge1, Noriyuki Masuda1, Nobuyuki Yamamoto2, Toshiaki Takahashi3, Haruyasu Murakami3, Koji Takeda4, Haruko Daga4, Kimio Yonesaka5, Hiroshi Tsukuda5, Kazuhiko Nakagawa6, Kaoru Tanaka6, Katsuyuki Kiura7, Nagio Takigawa7, Toyoaki Hida8, Takashi Seto9, Masanori Yokoba1, Shinzoh Kudoh10, Takeshi Takagaki11, Kazushige Shono11, Hideo Kitagawa11
1Department of Respiratory Medicine, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0375, Japan
2Third Department of Internal Medicine, Wakayama Medical University Hospital, 811-1 Kimiidera, Wakayama 641-8510, Japan
3Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan
4Department of Clinical Oncology, Osaka City General Hospital, 2-13-22 Miyakojima-hondori, Miyakojima-ku, Osaka 534-0021, Japan
5Medical Oncology, Izumi Municipal Hospital, 4-10-10 Fuchu-cho, Izumi, Osaka 594-0071, Japan
6Department of Medical Oncology, Kinki University Faculty of Medicine, 377-2 Onohigashi, Osakasayama, Osaka 589-8511, Japan
7Department of Respiratory Medicine, Okayama University Hospital, 2-5-1 Shikata-cho Kita-ku, Okayama, 700-8558, Japan
8Department of Thoracic Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan
9Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka 811-1395, Japan
10Department of Respiratory Medicine, Osaka City University, 1-5-7 Asahimachi, Abeno-ku, Osaka 545-8586, Japan
11Drug Development Division, Sumitomo Dainippon Pharma. Co., Ltd., 2-6-8 Doshomachi, Chuo-ku, Osaka 541-0045, Japan

Tài liệu tham khảo

Yamamoto, 2009, Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin, Drug Des. Devel. Ther., 2, 189 Morisada, 1989, Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts, Jpn. J. Cancer Res., 80, 69, 10.1111/j.1349-7006.1989.tb02247.x Noda, 1998, Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs, Investig. New Drugs, 16, 121, 10.1023/A:1006088907271 Chan, 1980, Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis, Cancer Res., 40, 1263 Johnson, 1992, Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters, Br. J. Cancer, 65, 751, 10.1038/bjc.1992.158 Morris, 1989, Alteration in doxorubicin and doxorubicinol plasma concentrations with repeated courses to patients, Ther. Drug Monit., 11, 380, 10.1097/00007691-198907000-00002 Inoue, 1989, Phase I and pharmacokinetic study of SM-5887, a new anthracycline derivative, Investig. New Drugs, 7, 213, 10.1007/BF00170860 Donelli, 1998, Pharmacokinetics of anticancer agents in patients with impaired liver function, Eur. J. Cancer, 34, 33, 10.1016/S0959-8049(97)00340-7 Schaaf, 2006, Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction, Clin. Cancer Res., 12, 3782, 10.1158/1078-0432.CCR-05-2152 Tani, 2005, Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride, Xenobiotica, 35, 1121, 10.1080/00498250500342746 Sumitomo Dainippon Pharma Co., Ltd. Calsed® for Injection [Interview form] (in Japanese). 〈http://www.info.pmda.go.jp/go/interview/2/400093_4235406D1020_2_013_1F.pdf〉, 2014. (accessed 18.09.15). Sumitomo Pharmaceuticals Co., Ltd. Calsed® (amrubicin hydrochloride) [Product information] (in Japanese). 〈http://www.pmda.go.jp/drugs/2002/P200200013/index.html〉, 2002. (accessed 18.09.15). Nagata, 2013, C609T polymorphism of NADPH quinone oxidoreductase 1 correlates clinical hematological toxicities in lung cancer patients treated with amrubicin, Clin. Med. Insights Oncol., 7, 31, 10.4137/CMO.S10839 Stewart, 1989, Altered protein binding of etoposide in patients with cancer, Clin. Pharmacol. Ther., 45, 49, 10.1038/clpt.1989.8 Nakai, 1998, Studies on the metabolic fate of amrubicin hydrochloride (SM-5887), a novel antitumor agent (I): blood concentration, distribution, metabolism and excretion after a single intravenous administration to rats, Drug Metab. Pharmacokinet., 13, 61, 10.2133/dmpk.13.61
Thông tin
Thông tin xuất bản

Cancer Treatment and Research Communications

Tập 9

81-87

Thông tin tác giả